748812-64-8Relevant academic research and scientific papers
COMPOUNDS AND USES THEREOF
-
Page/Page column 233, (2020/10/20)
The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
COMPOUNDS AND USES THEREOF
-
Page/Page column 226, (2019/10/15)
The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
NAPHTHYRIDINES AS INHIBITORS OF HPK1
-
Paragraph 0751; 0752, (2018/10/21)
Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P′1 group
Nantermet, Philippe G.,Barrow, James C.,Lindsley, Stacey R.,Young, Marybeth,Mao, Shi-Shan,Carroll, Steven,Bailey, Carolyn,Bosserman, Michele,Colussi, Dennis,McMasters, Daniel R.,Vacca, Joseph P.,Selnick, Harold G.
, p. 2141 - 2145 (2007/10/03)
Structural modifications of the aminopyridine P1 ′ group of imidazole acetic acid based TAFIa inhibitors led to the discovery of the aminocyclopentyl analog 28, a 1nM TAFIa inhibitor with CLT50 functional activity of 14nM but without selectivity against CPB. While not as active, aminobutyl derivative 27 provided an improved 6.7-fold selectivity for TAFIa versus CPB.
